

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

**WEST**[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)[Cases](#)**Search Results -**

Terms	Documents
(L2 or CD3) same (stabil\$ or oxidation or oxidized or degrad\$ or unstable)	93

Database:

US Patents Full-Text Database  
US Pre-Grant Publication Full-Text Database  
JPO Abstracts Database  
EPO Abstracts Database  
Derwent World Patents Index  
IBM Technical Disclosure Bulletins

Search:

L15

[Refine Search](#)[Recall Text](#)[Clear](#)**Search History****DATE:** Monday, March 11, 2002   [Printable Copy](#)   [Create Case](#)

**Set Name Query**

side by side

**Hit Count Set Name**

result set

*DB=USPT,PGPB,DWPI; PLUR=YES; OP=OR*

<u>L15</u>	(L2 or CD3) same (stabil\$ or oxidation or oxidized or degrad\$ or unstable)	93	<u>L15</u>
<u>L14</u>	(L2 or CD3) same (stabil\$ or oxidation or oxidized or degrad\$ or unstable)	93	<u>L14</u>
<u>L13</u>	L2 same (stabil\$ or oxidation or oxidized or degrad\$ or unstable)	19	<u>L13</u>
<u>L12</u>	L2 same (stabil\$ or oxid\$ or degrad\$ or unstable)	27	<u>L12</u>
<u>L11</u>	L2 same (stabil\$ or oxid\$ or degrad\$ or unstable)	27	<u>L11</u>
<u>L10</u>	L2 same (stabil\$ or oxid\$ or degrad\$ or unstable)	27	<u>L10</u>
<u>L9</u>	L2 same (stabil\$ or oxid\$ or degrad\$ or unstable)	27	<u>L9</u>
<u>L8</u>	L7	4	<u>L8</u>

*DB=USPT; PLUR=YES; OP=OR*

<u>L7</u>	L6 and H100A	4	<u>L7</u>
<u>L6</u>	L2 and (stabil\$ or oxid\$ or degrad\$ or unstable)	991	<u>L6</u>
<u>L5</u>	L2 and (stabil\$ or oxid\$ or degrad\$ or unstable)	991	<u>L5</u>
<u>L4</u>	L2 and (stabil\$ or oxid\$ or degrad\$ or unstable)	991	<u>L4</u>
<u>L3</u>	L2 and (stabil\$ or oxid\$ or degrad\$ or unstable)	942	<u>L3</u>
<u>L2</u>	OKT3 or anti-CD3 or OKT??3	1351	<u>L2</u>
<u>L1</u>	(OKT3 or anti-CD3) and (stabil\$ or oxidat\$ or degrad\$ or unstable)	921	<u>L1</u>

END OF SEARCH HISTORY

Wesner-Early, Caryn (ASRC)

*finished*

**From:** Hale, Mary  
**Sent:** Monday, March 11, 2002 10:28 AM  
**To:** Wesner-Early, Caryn (ASRC)  
**Cc:** Roark, Jessica  
**Subject:** FW: availability date of a reference

I will forward your request to Caryn (reference librarian). She will follow up with you.

Mary

-----Original Message-----

**From:** Roark, Jessica  
**Sent:** Monday, March 11, 2002 10:26 AM  
**T :** Hale, Mary  
**Subject:** availability date of a reference

I know Stephanie Publicker used to take care of these types of questions, but since she's gone I don't know who to ask, so I'm hopeful that you do ....

Applicant has indicated that they believe the reference below was not available until June of 1997, even though the cover date is April.

Can we please find out if this was released prior to May 23, 1997?

The reference is  
Kipriyanov et al. Protein Engineering vol 10, no 4 pp. 445-453, 1997.

Thanks so much!

*Jessica H. Roark*

CM1 9D04  
Mailbox 9E12  
Art Unit 1644  
703 605-1209

*TOP 248.P77  
P763*

*June 19  
from Oxford - \$150. for  
mail dates. Asked Linda  
for copy of cover from NLM  
3/11*

*Please return to*  
**Raffensperger, Linda**

~~6204556~~ 6204556

386722

**From:** Wesner-Early, Caryn (ASRC)  
**Sent:** Monday, March 11, 2002 12:24 PM  
**To:** Raffensperger, Linda  
**Cc:** Roark, Jessica; Hale, Mary  
**Subject:** FW: availability date of a reference

Linda -

This is from Oxford Univ. Press, which charges \$150 for mail dates. According to NLM's catalog, they're supposed to have it - would you please get a copy of the cover with date stamp for me? Thank you very much!

Caryn

Kipriyanov et al. Protein Engineering vol 10, no 4 pp. 445-453, 1997

-----Original Message-----

**From:** Hale, Mary  
**Sent:** Monday, March 11, 2002 10:28 AM  
**To:** Wesner-Early, Caryn (ASRC)  
**Cc:** Roark, Jessica  
**Subject:** FW: availability date of a reference

I will forward your request to Caryn (reference librarian). She will follow up with you.

Mary

-----Original Message-----

**From:** Roark, Jessica  
**Sent:** Monday, March 11, 2002 10:26 AM  
**To:** Hale, Mary  
**Subject:** availability date of a reference

I know Stephanie Publicker used to take care of these types of questions, but since she's gone I don't know who to ask, so I'm hopeful that you do ....

Applicant has indicated that they believe the reference below was not available until June of 1997, even though the cover date is April.

Can we please find out if this was released prior to May 23, 1997?

The reference is  
Kipriyanov et al. Protein Engineering vol 10, no 4 pp. 445-453, 1997.

Thanks so much!

*Jessica H. Roark*

CM1 9D04  
Mailbox 9E12  
Art Unit 1644  
703 605-1209

0269 239  
Scientific and Technical  
Information Center

MAR 12 RECD

PAT. & T.M. OFFICE

#1 PR787P

NO.4

1997

SEQ: SR005 57  
PROTEIN ENGINEERING

06/18/97

# PROTEIN ENGINEERING

Volume 10 number 4 April 1997



zero-linker single chain  
antibodies form 'triabodies'



PROPERTY OF THE  
NATIONAL  
LIBRARY OF  
MEDICINE

OXFORD  
UNIVERSITY  
PRESS

# PROTEIN ENGINEERING

## Executive editors

A.R.Rees

*School of Biology and Biochemistry, University of Bath, Bath, UK*

G.A.Petsko

*Rosenstiel Center, Brandeis University, Waltham, MA, USA*

## Associate editors

C.Craik

*Department of Pharmaceutical Chemistry and Biochemistry/  
Biophysics, University of California, San Francisco, CA, USA*

T.Imoto

*Faculty of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan*

H.Nakamura

*Biomolecular Engineering Research Institute, Osaka, Japan*

O.Pitsyn

*Russian Academy of Sciences, Pushchino, Russia*

## Forum editor

P.Argos

*EMBL, Heidelberg, Germany*

## Editorial board

T.Alber, *University of California, Berkeley, CA, USA*

F.Arnold, *California Institute of Technology, Pasadena, CA, USA*

T.Beppu, *University of Tokyo, Tokyo, Japan*

T.L.Blundell, *Birkbeck College, London, UK*

M.Caruthers, *University of Colorado, Boulder, CO, USA*

C.Chothia, *MRC, Cambridge, UK*

G.M.Clore, *NIH, Bethesda, MD, USA*

F.E.Cohen, *University of California, San Francisco, CA, USA*

W.F.DeGrado, *University of Pennsylvania School of Medicine,  
Philadelphia, PA, USA*

K.Dill, *UCSF, San Francisco, CA, USA*

A.R.Fersht, *University of Cambridge, Cambridge, UK*

A.Fontana, *CRIBI, Biotechnology Centre, Padua, Italy*

J.Gerlt, *University of Maryland, College Park, MD, USA*

B.Gutte, *Biochemisches Institut der Universität Zürich, Zürich,  
Switzerland*

M.Ikehara, *Protein Engineering Research Institute, Osaka, Japan*

M.Karplus, *Harvard University, Cambridge, MA, USA*

S.B.H.Kent, *The Scripps Research Institute, La Jolla, CA, USA*

Y.Kyogoku, *Osaka University, Osaka, Japan*

B.Matthews, *University of Oregon, Eugene, OR, USA*

C.R.Matthews, *Pennsylvania State University, Pennsylvania, PA*

R.E.Offord, *Centre Medicales Universitaires, Geneva, Switzerland*

S.B.Petersen, *SINTEF UNIMED, Trondheim, Norway*

R.T.Sauer, *MIT, Cambridge, MA, USA*

J.Schlessinger, *NYU, New York, USA*

J.Shi, *Chinese Biochemical Society, Shanghai, China*

G.P.Smith, *College of Arts and Science, Columbia, MI, USA*

M.Smith, *University of British Columbia, Vancouver, Canada*

D.Söll, *Yale University, New Haven, CT, USA*

M.J.E.Sternberg, *Imperial Cancer Research Fund, London, UK*

R.Stroud, *University of California, San Francisco, CA, USA*

J.Taylor, *Rutgers University, Piscataway, NJ, USA*

J.M.Thornton, *University College, London, UK*

J.E.Villafranca, *Agouron Pharmaceuticals, San Diego, CA, USA*

J.Wells, *Genentech Inc., San Francisco, CA, USA*

R.Wetzel, *1732 Hamilton Drive, Phoenixville, PA, USA*

G.Winter, *MRC, Cambridge, UK*

M.Zoller, *Ariad Pharmaceuticals, Cambridge, MA, USA*

## Cover design

A model of the scFv trimer (triabody). Three VH-VL molecules associate to form three active antigen combining sites, depicted with yellow VL CDR loops and blue VH CDR loops. For further details, see Kortt *et al.*, pages 423-433.

Published by Oxford University Press  
Oxford, UK

OXFORD  
UNIVERSITY  
PRESS

## Production editor

Wendy Neale, *Oxford University Press*